AGP Executive Report
Last update: 42 minutes agoHealthcare Cybersecurity: A Weill Cornell Medicine breach has renewed concerns about staff using unapproved AI tools with patient data, underscoring gaps in oversight and privacy safeguards. New Treatments: The FDA approved Gazyva for primary membranous nephropathy, Klygefa for generalized myasthenia gravis and at-home Igalmi for agitation linked to schizophrenia-spectrum and bipolar disorders. Research Watch: A Mayo Clinic study suggests blood levels of p-tau217, combined with age, sex and genetic risk, could help estimate future cognitive impairment risk; it is a risk estimate, not a diagnosis. Vaccines: A review of 18 flu seasons found median vaccine effectiveness of 39.5% against medically attended illness, with substantial year-to-year variation. Global Access: A World Bank-backed Nigerian program upgraded more than 2,500 primary care centers and helped fully immunize 16.6 million children. Care and Coverage: Apollo opened a clinic and diagnostic lab in Gurugram, while U.S. Rep. Ro Khanna renewed calls for Medicare for All, arguing private coverage could still supplement a public plan.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.